RBD-homodimer

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameRBD-homodimer
Drug Alias NameRBD-homodimer
ClassificationVaccines
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCSPC Pharmaceutical Group LtdWuhan Yzy Medical Science And Technology Co LtdWuhan Institute Of Virology, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Yzy Medical Science And Technology Co LtdWuhan Institute Of Virology, Chinese Academy Of SciencesCSPC Pharmaceutical Group Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A